Liminatus Pharma, Inc.

US$2.54As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:LIMNHealthcare
Country USA
PE (Fwd) •••
TSR 5Y CAGR (62.06%)
Div yield —
ROE —
Biotechnology
Beta (5Y) 0.78
PE TTM —
TSR TTM (96.35%)
Mkt cap US$3.412M
ROIC —
SE Grade™
Value
Quality
Moat
Consensus
Reference
$2.44
(3.78%)
41.75%
Hold 12|6|5|9|7
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.04
0.04
0.04
0.05
9.78%
18.27%
6.68%
22.56%
Revenue$M
0.176
0.172
0.169
0.164
13.95%
7.44%
3.07%
(1.60%)
Peers (US$3.412M)
Cap (US$)
PE
3.410M
—
Capital
TTM
5Y
10Y
Leveragex
0.434
0.228
0.250
EBIT/Intx
4.230
3.651
2.789
Own earn%
(12.83)
(16.75)
(0.13)
Sh yield%
21.76
54.78
54.62
Owners
Insiders/Inst%
13.17
73.78
Short interest%
3.21
SBC / revenue%
3.60
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
7
Op margin range%
4–10
$1 testx
—
Incr. ROIC%
3